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An understanding of metabolism is fundamental to comprehending 
the phenotypic behavior of all living organisms, including humans, 
where metabolism is integral to health and is involved in much of 
human disease. High quality, genome-scale ‘metabolic reconstructions’ 
are at the heart of bottom-up systems biology analyses and represent 
the entire network of metabolic reactions that a given organism is 
known to exhibit1. The metabolic-network reconstruction procedure 
is now well-established2 and has been applied to a growing number 
of model organisms3. Metabolic reconstructions allow for the con-
version of biological knowledge into a mathematical format and the 
subsequent computation of physiological states1,4,5 to address a variety 
of scientific and applied questions3,6. Reconstructions enable network-
wide mechanistic investigations of the genotype-phenotype relation-
ship. A high-quality reconstruction of the metabolic network is thus 
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Multiple models of human metabolism have been reconstructed, but each represents only a subset of our knowledge. Here we 
describe Recon 2, a community-driven, consensus ‘metabolic reconstruction’, which is the most comprehensive representation 
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models, providing a basis for manual curation or investigation of cell-specific metabolic properties. Recon 2 will facilitate many 
future biomedical studies and is freely available at http://humanmetabolism.org/.
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of interest to the community of researchers focused on the systems 
biology of metabolism of a target organism.
Of the reconstructions of human metabolism that have appeared to 
date, perhaps the most widely used is Recon 1 (ref. 7), which represents 
a knowledgebase and has also been converted 
into many predictive models. These models 
have been used for various biomedical appli-
cations, including the prediction of biomark-
ers for inborn errors of metabolism (IEMs)8, 
cancer drug targets9,10 and off-target drug 
effects11. Moreover, they have been used to 
evaluate missing metabolic functions system-
atically12,13 and to model host-microbe inter-
actions14,15. These studies demonstrated the 
potential of metabolic modeling to advance 
understanding of human metabolism in 
health and disease.
Various reconstructions of the human meta-
bolic network exist, with only partially over-
lapping content (ref. 16 and Supplementary 
Note 1). In addition to Recon 1, a global human 
metabolic reconstruction, EHMN (Edinburgh 
Human Metabolic Network)17, has also been 
published. Manually curated cell type–specific 
reconstructions are also available, including the 
comprehensive reconstruction of human hepa-
tocytes, HepatoNet1 (ref. 18), a small intestinal 
enterocyte reconstruction19 and other metabolic 
models for macrophages14, hepatocytes20 and 
kidney cells11. Moreover, a module for Recon 1 
that models acylcarnitine and fatty-acid oxidation (Ac-FAO) has recently 
been published8, which includes the metabolic surroundings of many 
biomarkers measured in the worldwide newborn screening program21. 
Recon 1 has also been used for the automated generation of cell-specific 
and tissue-specific models using various ‘omics’ data sets22,23, and to gen-
erate metabolic reconstructions semiautomatically for other mammals, 
such as the mouse24.
It is clear that ‘competing’ (that is, different) reconstructions and 
reconstruction approaches coexist, but all have the common goal of 
providing an up-to-date, comprehensive and high-quality reconstruc-
tion, either at the global or cell-specific scale. Rather than continu-
ing to duplicate efforts, a substantial fraction of the community has 
pooled resources to generate a consensus human metabolic recon-
struction from many of the sources cited above.
Here we describe Recon 2, a community-driven expansion of the glo-
bal human metabolic reconstruction, Recon 1. Much of this expansion 
was performed at reconstruction ‘jamboree’ meetings25, focused events 
at which domain experts apply their knowledge to refine and consolidate 
biochemical knowledge from existing reconstructions and published 
literature. Members of the Saccharomyces cerevisiae26,27 and Salmonella 
typhimurium LT2 (ref. 28) communities have used such a jamboree 
approach. The jamboree events provided the opportunity to establish 
common standards (and suitable links to other databases) for the con-
sensus reconstruction and the format of its content, to simplify its reuse 
and extension, and to increase its transparency and commitment to its 
development via participation of many stakeholders in the community. 
Here we also demonstrate the improved predictive capability of Recon 
2 over that of its predecessor. We mapped exometabolomic data29 onto 
Recon 2 and used proteomics data to generate cell type–specific metabolic 
models, which we then investigated for their functional properties.
RESULTS
Reconstruction approach
To assemble Recon 2, we added metabolic information present in four 
different resources (EHMN17, HepatoNet1 (ref. 18), Ac-FAO module8 
Recon 1
Recon 1.2
Recon 1.4
Recon 1.5
Recon 2
Consistency
testing
Consistency
testing
Debugging,
validation
Comp. EHMN
HepatoNet1
Ac-FAO module
hs_slEC611
Transport, absorption
Debugging,
validation
EHMN
Jamboree meetings
Figure 1 Overview of the community-driven reconstruction approach 
to assemble Recon 2. Comp. EHMN, compartmentalized EHMN; and 
hs_sIEC611, small intestinal enterocyte reconstruction.
Table 1 Comparison of major features of Recon 2 and its predecessor Recon 1
Property Recon 1 Recon 2
Total number of reactions 3,744 7,440
Total number of metabolites 2,766 5,063
Number of unique metabolites 1,509 2,626
Number of metabolites in extracellular space 404 642
Number of metabolites in cytoplasm 995 1,878
Number of metabolites in mitochondrion 393 754
Number of metabolites in nucleus 95 165
Number of metabolites in endoplasmic reticulum 235 570
Number of metabolites in peroxisome 143 435
Number of metabolites in lysosome 217 302
Number of metabolites in Golgi apparatus 284 317
Number of transcripts 1,905 2,194
Number of unique genes 1,496 1,789
Number of subsystems 90a 99
Number of blocked reactions (% of all reactions) 1,270 (34%) 1,603 (22%)
Number of dead-end metabolites 339b 1,176b
Size of Sc (m; n) 2,766; 3,744 5,063; 7,440
Number of linearly independent mass balances 1,070 2,774
Sparsity (% of nonzero entries in S) 0.1385 0.0837
Number of accomplished metabolic tasks 294 354
Mapped IEMs (% of all IEMs) 233 (71%) 248 (76%)
Number of unique genes causing IEMs 255 272
Number of IEMs affecting metabolic tasks (% of effective IEMs) 71 (36%) 98 (44%)
aBased on the subsystems categories defined for Recon 2. bAll but 32 dead-end metabolites Recon 1 have been resolved in 
Recon 2. Addition of new reactions and pathways (mostly from EHMN) led to the introduction of new dead-end metabolites, 
which was a starting point for subsequent curation efforts. cThe stoichiometric matrix (S) consists of m rows, each representing 
a single metabolite and n columns, each representing a single reaction. When a metabolite participates in a reaction the  
corresponding cell in the S matrix has a negative nonzero entry for substrates and a positive nonzero entry for products.
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and the human small intestinal enterocyte reconstruction19) to the 
content of Recon 1 following a step-wise process (Fig. 1). We added 
more than 370 transport and exchange reactions, based on a review 
of literature. We applied unambiguous third-party identifiers for cel-
lular compartments, metabolites, enzymes and reactions. We mapped 
the content from the DrugBank30 database, which lists experimental 
and US Food and Drug Administration−approved drugs, to individual 
enzymes and reactions. Ninety-five percent of metabolic reactions were 
mass-balanced and charge-balanced5,31 (Supplementary Table 1), 
except for those containing metabolites that have either no defined 
chemical formula or a generic formula. We tested Recon 2 for self-
 consistency2, a process that included gap analysis2 and leak tests32.
Benchmarking Recon 2 against Recon 1
Recon 2 accounts for 1,789 enzyme-encoding genes, 7,440 reactions and 
2,626 unique metabolites distributed over eight cellular compartments, 
which is a large increase in comprehensiveness relative to Recon 1 
(Table 1). Such an increase in scope does not necessarily constitute an 
improvement in utility over the previous ver-
sion: expanding the reconstruction to resolve 
existing gaps and dead-end metabolites may 
introduce additional gaps and dead ends 
elsewhere. To demonstrate an improvement 
of the network, both coverage and functional 
improvements must be considered.
To quantify the overall improvements 
achieved through the community-driven 
expansion and refinement in the global human 
metabolic reconstruction, we compared the 
information coverage, topological and func-
tional properties of Recon 2 with those of 
Recon 1 (Table 1). The reaction content was 
almost doubled, much of which belonged 
to one of the nine new pathways (Fig. 2). 
Moreover, 62% (61/99) of the existing path-
ways have been expanded in Recon 2, and 
reaction coverage in 29 pathways, account-
ing for 16.5% (1,231/7,440) of the reactions, 
remained unchanged. A total of 307 dead-end 
metabolites (metabolites that are either only 
produced or only consumed in the reconstruc-
tion) from Recon 1 were resolved in Recon 2, 
whereas 32 remained as participants in only 
one reaction. As a result of the expansion, 
1,144 new dead-end metabolites, mostly from 
EHMN, were introduced. These will need to be 
connected to the rest of the network in subse-
quent efforts. Blocked reactions cannot carry 
a nonzero flux in any steady-state condition 
because they contain one or more dead-end 
metabolites or are in a linear pathway with such 
reactions. The expanded coverage of metabolic 
information resolved 827 blocked reactions 
present in Recon 1, and 443 blocked reactions 
remained (Table 1). The number of remain-
ing and new blocked reactions and dead-end 
metabolites highlights that this current update 
is not intended to be the final compendium of 
human metabolism, but it is a major advance 
over Recon 1 and represents our current, con-
tinually evolving knowledge.
A metabolic task is defined as a nonzero flux through a reaction 
or through a pathway leading to the production of a metabolite B 
from a metabolite A. Examples of such tasks include the synthesis 
of all known precursors to produce a cell (biomass reaction; 
Supplementary Note 2) and the generation of energy via oxidative 
phosphorylation or fermentation (Supplementary Table 2). A total 
of 354 metabolic tasks were defined. Although a particular cell type 
is not capable of fulfilling all these metabolic tasks, Recon 2 should 
be able to fulfill these tasks because it is a global metabolic recon-
struction. Recon 2 carried a nonzero flux for all tasks, compared 
with Recon 1, which achieved this functionality for only 83% of the 
tasks (Table 1).
To benchmark the models derived from both reconstructions 
against an independent data set, we used a manually assembled 
compendium of IEMs8 as a gold standard. This compendium 
accounts for 330 IEMs, such as phenylketonuria and orotic aciduria, 
along with their known metabolite biomarkers. As Recon 2 cap-
tured more metabolic genes, more IEMs could be mapped (Table 1). 
Xenobiotics metabolism
Fraction of reactions in Recon 1 and Recon 2
Fraction of reactions in Recon 2 only
Vitamin E metabolism
Squalene and cholesterol synthesis
Lipoate metabolism
Linoleate metabolism
Glycosphingolipid metabolism
Dietary fiber binding
Arachidonic acid metabolism
Androgen and estrogen synthesis and metabolism
Unassigned
Eicosanoid metabolism
Miscellaneous
Fatty acid synthesis
Fatty acid oxidation
CoA synthesis
Bile acid synthesis
Transport, extracellular
Tetrahydrobiopterin metabolism
Urea cycle
Tyrosine metabolism
Pyrimidine synthesis
Vitamin A metabolism
Purine catabolism
Vitamin D metabolism
Vitamin B2 metabolism
Phosphatidylinositol phosphate metabolism
Exchange/demand reaction
Transport, endoplasmic reticular
Fructose and mannose metabolism
Oxidative phosphorylation
Transport, mitochondrial
Methionine and cysteine metabolism
Transport, peroxisomal
Tryptophan metabolism
Starch and sucrose metabolism
Pyrimidine catabolism
Transport, lysosomal
Vitamin B12 metabolism
Heme degradation
CoA catabolism
Histidine metabolism
Glutathione metabolism
Glycerophospholipid metabolism
Cholesterol metabolism
Valine, leucine and isoleucine metabolism
Heme synthesis
Selenoamino acid metabolism
Alanine and aspartate metabolism
Steroid metabolism
Purine synthesis
Pentose phosphate pathway
Aminosugar metabolism
Glycolysis/gluconeogenesis
Glutamate metabolism
Glycine, serine, alanine and threonine metabolism
Vitamin С metabolism
Vitamin B6 metabolism
Propanoate metabolism
Folate metabolism
Citric acid cycle
Arginine and proline metabolism
ROS detoxification
Taurine and hypotaurine metabolism
Lysine metabolism
β-Alanine metabolism
Transport, Golgi apparatus
Nucleotide interconversion
Sphingolipid metabolism
Transport, nuclear
Pyruvate metabolism
0 0.2 0.4 0.6 0.8 1.0
Figure 2 Pathway coverage in Recon 1 and Recon 2. Only pathways with added reaction content in 
Recon 2 are shown. The 29 pathways that have identical reaction content in both reconstructions 
are not shown.
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In Recon 2, almost all of the mapped IEMs 
affected the reaction activity, as no com-
plementary isoenzymes are known for 
the absent enzymes (consistent with their 
occurrence as IEMs). We compared the pre-
dictive potential of Recon 2 and Recon 1 for 
associated biomarkers for the mapped IEMs 
(Fig. 3), in a process analogous to gene-
 deletion studies in microbial modeling. 
Recon 2 predicted 54 reported biomarkers for 
49 different IEMs, with an accuracy of 77%. 
The coverage of predicted biomarkers and 
the accuracy was much lower for Recon 1, 
with 31 reported biomarkers for 29 IEMs 
and an accuracy of 63% (Fig. 3). This com-
parison demonstrates that the increased 
scope of Recon 2 led to a higher coverage of IEM-related biomark-
ers mapped and to an increase in predictive power.
Based on the accurate predictive capability of Recon 2 for biomark-
ers and for the metabolic tasks, the benchmarking demonstrated an 
increase in both scope and predictive accuracy of Recon 2 relative to 
its predecessor.
Recon 2 captures the majority of known exometabolites
Recon 2 accounts for 642 extracellular metabolites, which should be 
found in cell culture medium and in biofluids such as plasma and 
urine. When comparing these extracellular metabolites with a reported 
subset of a cancer exometabolome33 consisting of 140 metabolites, the 
majority of the metabolites were indeed present in the extracellular 
compartment (Fig. 4a and Supplementary Table 3). Using a flux vari-
ability analysis34, we predicted in silico the uptake and release profile 
of Recon 2. Recon 2 had high sensitivity in predicting correctly the 
uptake and release for 91 metabolites (sensitivity values of 0.92 and 
0.94, respectively; Supplementary Table 3). However, the capability 
of Recon 2 to predict true negatives (that is, metabolites that cannot 
be taken up or released) was very low. For instance, 14% (13/91) of 
the metabolites could not be released by any of the tested cancer cell 
lines, whereas all but one metabolite was released in silico. As Recon 2 
represents the combined metabolic capability of all cells in the human 
body, not just of neoplastic cells, the low sensitivity is expected. The 
mismatches could be used to guide the assembly of cancer-specific 
metabolic models or to refine an existing cancer metabolic model9. 
It is noteworthy that Recon 2 contains many more extracellular 
metabolites (551), which were not seen in the experimental exome-
tabolome, presumably in part because of the targeted liquid chroma-
tography–tandem mass spectrometry method used33, as more than 
1,000 metabolite peaks can easily be observed in human serum35.
We also compared the Recon 2 exometabolome and the metabolites 
reported in the Human Metabolome Database (HMDB)36 as being 
detectable in biofluids (Fig. 4b). Biofluid information could be found 
for about half of the metabolites in Recon 2 identified in the HMDB. 
About 44% of these metabolites were also present in the extracel-
lular compartment, indicating that there are still some transport and 
metabolic routes missing in Recon 2.
In summary, Recon 2 captured many of the reported exometabo-
lites and biofluid metabolites, illustrating its comprehensiveness and 
the value of annotating with multiple metabolite identifiers, permit-
ting the integration of data from many sources.
Generation of draft, cell type–specific models
A metabolic reconstruction is unique to a genome, and thus to an 
organism, but condition-specific constraints can be applied to create 
a condition-specific model from the reconstruction. Thus, one 
reconstruction can give rise to many models. We mapped expres-
sion data from the Human Protein Atlas37 for 65 cell types, capturing 
information for 25% (451/1,789) of the unique gene products in 
Recon 2 (Supplementary Fig. 1). These data were used together with a 
 published algorithm5,38 to generate 65 draft cell type–specific metabolic 
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Figure 3 Predicted biomarkers for IEMs.  
(a) Comparison of the prediction accuracy 
of Recon 1 and Recon 2 against the gold 
standard8. (b) Correct and incorrect predictions. 
IEMs and biomarkers are sorted by subsystem. 
Bright yellow, amino-acid metabolism; green, 
central metabolism; blue, hormones; yellow, 
lipid metabolism; pink, nucleotide metabolism; 
lilac, vitamin and cofactor metabolism. Blue and 
red shading corresponds to predicted increase 
and decrease in biomarker, respectively. Blue 
and red lines represent reported increase 
and decrease of the biomarker in plasma, 
respectively. 34dhphe, 3,4-dihydroxy-l-
phenylalanine; 3mlda, 3-methylimidazoleacetic 
acid; 5htrp, 5-hydroxy-l-tryptophan; bhb,  
(R)-3-hydroxybutanoate; tetdec2crn, 
tetradecadienoyl carnitine; tetdece1crn, 
tetradecenoyl carnitine. (See Supplementary 
Table 5 for complete names of the IEMs.)
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models consisting of 2,426 ± 467 reactions (± s.d.) and 1,262 ± 204 tran-
scripts (Fig. 5). Of the 593 core reactions present in all cell-type models, 
more than half of them were transport reactions (Supplementary 
Table 4). Furthermore, 33% (2,463/7,440) of the Recon 2 reactions 
appeared in none of the cell-type models, with almost 40% (968/2,463) 
of those belonging to the subsystem ‘lipids’ (Supplementary Fig. 2). 
Based on the cell type–specific models, 26% (457/1,789) of the genes 
in Recon 2 represent the core genes (that is, they were found in all cell 
type–specific models), and 58% of the genes were part of two or more 
models. Only 32 genes were specific to a particular cell type–specific 
model. The remaining 14% (245/1,789) of the genes were not cap-
tured by any cell type–specific model. The glandular-cell models were 
highly correlated based on presence and absence of genes and reactions, 
whereas epithelial-cell models were less correlated (Supplementary 
Figs. 3,4). Overall, we observed higher correlation on the subsystems 
level with the ‘transport’ subsystem being the most correlated one, 
highlighting the importance of nutrient uptake and secretion for cel-
lular function (Supplementary Figs. 3,5).
The automatically generated hepatocyte model captured 61% 
(1,109/1,823) of the reactions present in a published hepatocyte 
model20, whereas 64% (1,932/3,041) of this model’s reactions were 
not in the published model. When comparing our draft hepato-
cyte model with the published hepatocyte model, HepatoNet1 
(ref. 18), 1,098 reactions were present in both, whereas 64% 
(1,943/3,041) were unique to our model and 57% (1,441/2,539) of 
reactions were unique to HepatoNet1. Such discrepancies between 
our draft model and the published cell-type models may serve as 
an indication of areas of attention for subsequent manual curation 
and assessment.
We investigated the metabolic tasks that each cell type–specific 
model can perform. On average, the cell type–specific models had 
nonzero flux for 174 ± 32 of 354 metabolic tasks. Thirty-one meta-
bolic tasks could be carried out by all such models, many of which 
tested different aspects of amino-acid metabolism, and 44 metabolic 
tasks had a zero flux for all models. Of all 
of these models, only the hepatocyte model 
could generate urea, via the urea cycle, which 
is consistent with current knowledge. Small 
intestinal enterocytes are also capable of urea 
synthesis but are currently not captured by 
the Human Protein Atlas37. Notably, 25% 
(16/65) of the models had a nonzero flux 
through the biomass reaction, which means 
that these models contain all necessary reac-
tions either to take up or synthesize all the 
precursors defined in the biomass reaction.
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4,390
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3,569 4,488 551 489 1,586
Recon 2 total
metabolites
Recon 2
extracellular
metabolites
Cancer exo-
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Recon 2 metabolites
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b
Figure 4 Comparison of metabolomic data with the extracellular 
metabolites present in Recon 2 metabolites. (a) Comparison with the 
cancer exometabolome33 (see Supplementary Table 3 for a breakdown of 
the 18 cancer exometabolites that are absent from Recon 2, the 31 for 
which no exchange reaction is present, and the 91 for which uptake or 
release profile comparisons could be performed). (b) Comparison with the 
HMDB36 (see Supplementary Fig. 6).
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Figure 5 Summary properties of the 65 draft 
cell type–specific models. (a) Distribution 
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evenly. In contrast, most of reactions in the 
core reaction set, consisting of 593 reactions, 
belonged to the transport subsystem. The 
second largest subsystem in Recon 2, lipid 
metabolism, represented only a small fraction of 
the core reaction set.
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Recon 2 includes mappings of drug actions to enzymes
Recon 2 includes 2,657 metabolic enzymes and 1,052 enzymatic com-
plexes, many of which are known drug targets. We queried DrugBank30, 
a comprehensive resource that includes drug-to-enzyme mappings for 
>6,000 small-molecule and peptide or protein drugs, to allow drugs 
(and their actions) to be mapped to the enzymes of Recon 2. We found 
that 1,290 drugs were mapped to 308 enzyme and enzymatic com-
plexes. This equated to 3,168 drug-enzyme or drug-complex interac-
tions, of which 841 were specified as inhibitory. These mappings are 
included in both the global reconstruction and the cell type–specific 
models, providing a starting point for the simulation of drug actions 
with both constraint-based and kinetic modeling1,39,40.
DISCUSSION
Our results illustrate that (i) Recon 2 is a comprehensive metabolic 
resource and serves as an effective predictive model; (ii) mapping of 
exometabolomic data onto Recon 2 provides a starting point for fur-
ther iterative expansion and refinement; (iii) protein expression data 
and Recon 2 can be used to generate draft cell type–specific metabolic 
models; and (iv) comparative analysis of cell type–specific models 
provides insight into alternate metabolic strategies.
The metabolic reconstruction process is inherently iterative, as 
increasing biochemical and genomic knowledge is generated about the 
target organism over time. This calls for periodic updates and expansion 
in the coverage and content of a reconstruction2; thus we adopted the 
‘Recon 1’ and ‘Recon 2’ naming convention in analogy with the ‘build 
X’ convention for the assembly of the human genome sequence and 
similar conventions used in the naming of iteratively released meta-
bolic reconstructions in yeast27. The published resources for human 
metabolism differ in syntax and content; for instance, a comparison of 
five different resources revealed that only a small number of overlap-
ping reactions were present in all resources (ref. 16 and Supplementary 
Note 1). These discrepancies make it difficult to compare and combine 
metabolic reconstructions. We overcame this issue by manually curating 
overlapping entries. The presented consensus reconstruction of human 
metabolism is fully semantically annotated41 with references to persist-
ent and publicly available chemical and gene databases, unambiguously 
identifying its components and increasing its applicability for third-
party users (including automated processing by software). Moreover, 
the work expanded beyond combining existing resources, by adding 
transport and absorption reactions known to occur in epithelial cells of 
the gastrointestinal tract and the renal tubules. Drug information was 
mapped from DrugBank30, providing a comprehensive starting point 
to investigate off-target effects of drugs11 or to obtain information on 
known drugs for drug target predictions studies9.
We improved the predictive potential of Recon 2 through the 
addition of new content. The number of IEMs that Recon 2 captured 
and the accurate prediction of known biomarkers (Fig. 3) demon-
strate the substantial functional advancement achieved through the 
expansion and refinement. We illustrated the potential of the con-
straint-based modeling approach by generating a global model, not 
tailored to a particular application, which can nonetheless predict 
accurately many distinct biomarkers for many IEMs. In addition, 
Recon 2 also predicted some previously undescribed biomarkers, 
which have not yet been measured8. With the increasing sophistica-
tion of targeted metabolomic approaches42, biomarker predictions 
may help to guide such analyses. Additionally, large cohort studies 
have started to connect genotype with metabotype43. As Recon 2 
captures most of the measured metabolites, it provides a resource 
for investigating the connection between genotype and metabotype 
and ultimately phenotypes based on these data.
We mapped two large-scale exometabolome resources to Recon 2, 
showing that Recon 2 captures most of the exometabolites and 
biofluid metabolites reported therein. Although this illustrated the 
comprehensiveness of the reconstruction, it also highlighted that 
the information content in the reconstruction is still not complete. 
Many algorithms exist that may assist in proposing missing metabolic 
and transport reactions in Recon 2 and thus aid subsequent manual 
curation (Supplementary Note 3)12,13,44. It is also clear that reported 
biofluid metabolites36 might be of dietary and/or microbial origin, as 
the mammalian gut microbiota has been found to affect blood com-
position45 and metabolism46 substantially. To determine the origin 
of the biofluid metabolites, a comprehensive computational model 
accounting for microbial metabolism, human metabolism and dietary 
composition is needed.
Recon 1 has been used together with omics data to generate compre-
hensive sets of draft cell type–specific metabolic reconstructions23,38. 
We mapped data from the Human Protein Atlas37 onto Recon 2 to gen-
erate 65 cell type–specific metabolic models automatically. Although 
protein expression data were available for only one-quarter of the 
Recon 2 gene products, to our surprise the draft cell type–specific 
models contained many reactions and genes (Fig. 5). The size of 
many published cell type–specific models, which have been at least 
in part generated automatically, is comparable23,37. In a comparison 
of our automatically generated hepatocyte model with two published 
models18,20, we found reasonable overlap, even though these models 
were assembled using different methods and information. Our auto-
matically generated hepatocyte model contained alternate reactions, 
which reflect the proteomic input data and the algorithm used. For 
instance, the protein expression data were limited to those that had a 
high confidence level, but by including lower-confidence expression 
data, combined with a weighting scheme, one may obtain alternate 
draft models. Moreover, the algorithmic approach currently does not 
consider transcriptional regulation, thermodynamic constraints and 
the synthesis cost for each enzyme and its building blocks. Ultimately, 
manual inspection and curation will be necessary to obtain more 
versatile, comprehensive, predictive cell type–specific models.
To assess the functionality of the automatically generated cell type–
specific models, we tested 354 metabolic tasks. One-quarter of the 
models could produce all defined biomass precursors, thus enabling 
them to simulate cell growth. A review of literature revealed that some 
of these cell types are indeed known to divide in vivo upon injury 
or induction by specific growth factors. The protein expression data 
are generated in many cases on tissue biopsies. The growth capabili-
ties could not have been determined from the omics data alone, and 
this highlights the importance of computational modeling to analyze 
experimental data. Moreover, the metabolic activity profile, combined 
with the set of active exchange reactions, could be compared with cell 
type–specific literature to evaluate the correctness of the metabolic 
content of each model and to refine the models by enabling or disa-
bling additional tasks, exchange reactions and metabolic content.
We anticipate that, as a result of the improvements over its pred-
ecessor, Recon 2 will be widely used and will enable the explora-
tion of new frontiers in research in human metabolism and its role 
in health and disease. The global model is available via a database 
at http://humanmetabolism.org/, in SBML format at Biomodels 
(http://identifiers.org/biomodels.db/MODEL1109130000) and as 
Supplementary Data 1.
METHODS
Methods and any associated references are available in the online 
version of the paper.
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ONLINE METHODS
Reconstruction approach. The reconstruction of the expanded and refined 
global human metabolic network, Recon 2, was performed in multiple stages. 
Intermediate versions of Recon 2 are referred to as ‘Recon 1.x’.
Jamboree work. The jamboree meetings were used to discuss strategies com-
bining the content of the two reconstructions and the required quality control 
of the finished consensus. The strategy was to start with the compartmen-
talized Recon 1 reconstruction and incrementally add reactions from the 
EHMN reconstruction.
Initially, automated approaches31 were applied to Recon 1 (ref. 7) and the 
EHMN17 to solve the problem of inconsistent naming of the components 
(compartments, metabolites, genes and reactions). The remaining compo-
nents that could not be automatically matched to existing database entries were 
manually annotated during the jamboree meetings. Cellular compartments 
were annotated with Gene Ontology (GO) terms. Metabolites were anno-
tated with terms from the resources Chemical Entities of Biological Interest 
(ChEBI), Kyoto Encyclopedia of Genes and Genomes (KEGG) Compound, 
PubChem Compound and HMDB36, and also IUPAC International Chemical 
Identifier (InChI) terms where possible. Where metabolites were not present 
in any existing data resources, many were submitted as new entries to 
ChEBI. Enzymes were annotated with Enzyme Classification (EC) terms, US 
National Center for Biotechnology Information (NCBI) Gene identifiers and 
UniProt terms.
The jamboree meetings also focused on manual curation of the reconstruc-
tion content. Reactions were curator-validated and annotated with PubMed 
literature references, standardized GO evidence codes (Supplementary 
Table 6) and a confidence scoring system ranging from 0 (no evidence) to 4 
(biochemical evidence)2. Metabolites and enzymes were assigned to appro-
priate cellular compartments. Metabolic reactions were checked to ensure 
correct stoichiometry, irreversibility, correct assignment of gene association 
and enzyme rules, and mass and charge balancing, and appropriate transport 
reactions were added.
Post-jamboree work. For reactions that occurred in both Recon 1 and EHMN, 
the co-occurrence was considered to be evidence for their inclusion in 
Recon 1.x. The jamboree teams had manually evaluated reactions from Recon 1, 
and reactions unique to the compartmentalized EHMN were added to 
Recon 1.x only if they were mass- and charge-balanced. The charge state of 
metabolites was calculated at an assumed pH of 7.2. Reactions were mass- and 
charge-balanced where possible, as defined in Recon 1. Where additional metab-
olites and reactions were added from sources such as EHMN, the SuBliMinaL 
Toolbox31 and COBRA Toolbox5 were used to apply mass and charge balancing. 
In cases where reactions contained ‘generic’ compounds (containing –R and –X 
groups), which were used to represent a set of specific compounds to decom-
plexify the reconstruction, mass and charge balancing was not possible. An 
investigation into thermodynamic consistency of Recon 1 reactions47 proposed 
changes to a small subset of reactions, which were also incorporated. We also 
updated the gene list based on changes introduced from build 35 to build 37, 
which includes the removal or replacement of obsolete gene entries.
Subsequently, the Recon 1.x content was extended to account for the content 
in the published HepatoNet1 (ref. 18) reconstruction. The same procedure 
for converting HepatoNet1 to the syntax of Recon 1.x was used as described 
above. As HepatoNet1 is a pruned and cell-specific stoichiometric model, 
some conventions were different from that in Recon 1.x. Most importantly, the 
implementation of lipids as some specific pools with fixed fatty-acid distribu-
tions was incompatible with the flexible and less specified R system in Recon 
1.x, and therefore the lipid reactions were excluded from the merging process. 
HepatoNet1 accounts for multiple extracellular compartments. For simplicity, 
all of the HepatoNet1 extracellular metabolites and reactions were assumed 
to be present in a single common extracellular compartment, following the 
convention of Recon 1.
Content from both the recently published acylcarnitine–fatty acid oxida-
tion module8 and the metabolic reconstruction for human small intestinal 
enterocytes19 were also added to Recon 1.x. The latter accounts for two extra-
cellular compartments (luminal and blood side). Again, a single extracellular 
compartment was assumed.
As a final step of expanding the content of the global human metabolic 
reconstruction, thorough literature research was performed to identify missing 
transport and absorption reactions in Recon 1.x. The reconstruction of this 
module was performed as described previously2.
The reconstruction assembly and conversion to a mathematical model was 
done using rBioNet48. The uniqueness of reactions in Recon 1.x was deter-
mined, and multiple rounds of self-consistency testing and functional assess-
ment of the model performed using established procedures2, which included 
gap analysis2, leak tests32 and a functional analysis.
The resulting reconstruction was finalized and named Recon 2.
Leak analysis. A model of Recon 2 was used for the leak analysis, in which 
all unbalanced reactions were considered inactive by constraining their lower 
and upper bound flux bounds to zero. The test of mass leaks was performed 
with a simulation procedure defined in the tutorial of FASIMU32, by looking 
for steady-state flux distributions that either (i) consume no substrates and 
generate an output or (ii) consume substrates but do not generate products. 
The flux distributions representing a leak were analyzed manually to identify 
causative unbalanced reactions. After balancing or deleting the corresponding 
reaction(s), the test was repeated until no additional leaks were observed. In all 
simulations with Recon 1 and Recon 2, all metabolites with defined exchange 
reactions could be taken up and secreted. Reaction constraints applied to the 
leak-free Recon 2 model that was used for all computations in this study are 
listed in Supplementary Table 7.
Topological analysis. Performing flux variability analysis34, while permitting 
constrained uptake and secretion of all metabolites with defined exchange 
reactions has been defined, allowed the identification of blocked reactions 
in Recon 1 and Recon 2, that is, reactions that could not carry any nonzero 
flux under this simulation condition. Dead-end metabolites were identified as 
described previously2. Compound participation was calculated as described 
by previously1 (Supplementary Note 4).
Functional characterization of Recon 1 and Recon 2. The metabolic capac-
ity of the network was demonstrated by testing nonzero flux values for 354 
metabolic tasks, which were based on Recon 1 and ref. 19. For each of the 
simulations a steady-state flux distribution was calculated. Each metabolic task 
was optimized individually by choosing the corresponding reaction in either 
Recon 1 or Recon 2, if present, as objective function and maximized the flux 
through the reaction (see Supplementary Table 2).
Mapping the compendium of inborn errors of metabolism and predicting 
biomarkers. The compendium of IEMs8 contains information about causative 
genes and known biomarkers for 330 distinct IEMs. Using gene-reaction asso-
ciations, the IEMs were mapped onto Recon 1 and Recon 2. A gene-associated 
reaction was affected if no isoenzyme existed that was not known to cause 
an IEM. To predict biomarkers for each IEM affecting one or more reaction, 
the method reported in ref. 49 was followed. Changes in biomarkers result-
ing from an IEM were compared with reported biomarkers for each IEM. 
A Fisher’s exact test was applied to compute the hypergeometic P value. This 
analysis was performed for Recon 1 and Recon 2. Mapped IEMs are listed in 
Supplementary Table 5.
Cancer exometabolome mapping. Information related to a cancer exome-
tabolome33, which reported consumed and secreted compounds in the culture 
medium, was manually mapped to the metabolites of Recon 2 (Supplementary 
Table 3). Flux variability analysis was performed on the exchange reactions, 
and the uptake-secretion capability was compared with reported consumption 
and secretion capability of the cancer cells.
Biofluid metabolome mapping. Information about the biofluid location of 
metabolites was obtained from the MNDB (version August 2012)36. Mapping 
was performed through HMDB identifiers, which were recorded during the 
reconstruction process.
Protein expression data mapping. Protein expression data were downloaded from 
the Human Protein Atlas37 in May 2012 and Ensembl identifiers were mapped onto 
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Recon 2 gene products. Gene products with moderate/medium and strong/high 
levels of expression were assumed to be present, and all others were assumed to be 
absent. Gene products without data in a cell type were assumed to be absent.
Generation of a draft cell type–specific model compendium. For each cell 
type, the presence and absence information from the protein expression data 
was used as input for the MinMax algorithm38, which was implemented in 
the COBRA Toolbox5. The biomass reaction and a reaction representing ATP 
hydrolysis were subsequently added to each model. The IEM compendium was 
mapped onto each cell type–specific draft model as described above. For each 
model, its capability to perform the defined metabolic tasks was tested.
SBML models. Recon 2 is available in the Systems Biology Markup Language 
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